Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristics
This retrospective study demonstrated that patients with advanced non-small cell lung cancer who experienced any-grade or grade 1-2 immune-related adverse events (irAEs) with immune checkpoint inhibitor plus chemotherapy (ICI+Chemo) as first-line treatment regimen had significantly longer progression-free survival (PFS; <i>p</i> < 0.001) and overall survival (OS; <i>p</i> < 0.05) compared with patients without any irAE. Three variables were identified as predictors of favorable PFS and OS: absence of baseline brain metastasis (<i>p</i> < 0.05), receiving first-line ICI+Chemo (<i>p</i> < 0.01), and occurrence of any grade adverse events (<i>p</i> < 0.001). Using these three variables, two nomograms were generated to predict PFS and OS, which were validated using two independent cohorts treated with Chemo or ICI+Chemo (<i>n</i> = 161) or ICI monotherapy (<i>n</i> = 109). Patients with low scores in discovery and validation cohorts consistently had significantly longer PFS (<i>p</i> < 0.001) and OS (<i>p</i> < 0.05) than those with high scores. Our findings provide preliminary evidence of the clinical utility of a nomogram in prognosticating ICI-treated patients.
Authors
- Ruiguang Zhang
- Zhe Huang (ORCID: https://orcid.org/0000-0002-3524-2806)
- Qinqin Xu (ORCID: https://orcid.org/0000-0002-1359-8895)
- Fan Tong (ORCID: https://orcid.org/0000-0002-4333-0128)
- Shaoding Lin
- Haoyue Qin
- Xiaorong Dong (ORCID: https://orcid.org/0000-0001-7470-1836)
- Lin Zhang (ORCID: https://orcid.org/0000-0003-0018-3903)
- Xing Zhang (ORCID: https://orcid.org/0009-0004-8215-8000)
- Zhan Wang (ORCID: https://orcid.org/0009-0003-2797-530X)
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Li Deng (ORCID: https://orcid.org/0000-0002-7270-2998)
- Zhaoyi Liu (ORCID: https://orcid.org/0000-0001-8563-7665)
- Huan Yan (ORCID: https://orcid.org/0000-0001-7546-8087)
- Wenjuan Jiang (ORCID: https://orcid.org/0009-0006-4068-8892)
- Wenhuan Guo
- Liang Zeng (ORCID: https://orcid.org/0000-0002-4755-775X)
- Lianxi Song
- Nong Yang
Institutions
- Union Hospital (HK)
- Central South University (CN)
- Hunan University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Ninth People's Hospital (CN)
- Hunan Cancer Hospital (CN)
- Qinghai Provincial Peoples Hospital (CN)
- Huazhong University of Science and Technology (CN)
- University of South China (CN)
Publication Details
- Journal
- iScience
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1016/j.isci.2024.110910
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Natural Science Foundation of China
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China